Fig. 2
From: Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN
Expression, purification and binding affinity of anti-CD79B-scFv. a Volcano map of whole gene expression matrix (GSE555) for CML patients. GEO2R was used for online analysis of the differential gene datasets; b The expression level of CD79B in leukemia cell lines detected by Western blotting. c Localization of CD79B (green) in K562 cells (scale: 10 μm). d SDS-PAGE of purified anti-CD79B-scFv with Coomassie blue staining; e The binding capability of anti-CD79B-scFv with leukemia cell lines detected by ELISA; f The binding of anti-CD79B-scFv with K562 cells determined by flow cytometry; g Binding specificity of anti-CD79B-scFv with different cells detected by Western blotting. ns: no significance, **P < 0.01 versus control group